Safety and Efficacy Study of Lung Cancer Stem Cell Vaccine

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2015 Mar 7

PMID 25743632

Citations 3

Authors

Mao Lin

Shu-Ying Li

Ke-Cheng Xu

Zheng-Ping Liu

Feng Mu

Yuan-Ying Yuan

Xiao-Hua Wang

Ji-Bing Chen

Qiao Li

Affiliations

Soon will be listed here.

Abstract

In this trial, lung cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between February and September 2014, we enrolled 90 patients who met the enrollment criteria and assigned them to three groups (n = 30). Throughout the trial, injection site reaction was the most common reaction (63 %), and fever was least common (16 %); however, there was no difference among the three groups. When the immune responses pre- and post-vaccination were compared, we found that the CSC-nonspecific and CSC-specific responses were both significantly enhanced in the medium- and high-dose groups. This study is the first clinical trial of a lung CSC vaccine and preliminarily proves its safety and efficacy.

Citing Articles

Cancer stem cells: advances in knowledge and implications for cancer therapy.

Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z Signal Transduct Target Ther. 2024; 9(1):170.

PMID: 38965243 PMC: 11224386. DOI: 10.1038/s41392-024-01851-y.

Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model.

Eini L, Naseri M, Karimi-Busheri F, Bozorgmehr M, Ghods R, Madjd Z J Cancer Res Clin Oncol. 2022; 149(7):4101-4116.

PMID: 36040667 DOI: 10.1007/s00432-022-04303-8.

Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells.

Fiorentino S, Uruena C, Lasso P, Prieto K, Barreto A Front Oncol. 2020; 10:1334.

PMID: 32850424 PMC: 7426739. DOI: 10.3389/fonc.2020.01334.

References

Choudhury A, Palma M, Mellstedt H . The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer. 2008; 9 Suppl 1:S37-44. DOI: 10.3816/clc.2008.s.006. View

Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F . Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol. 2007; 601:123-31. DOI: 10.1007/978-0-387-72005-0_13. View

Sharma A, Moore W, Lanuti M, Shepard J . How I do it: radiofrequency ablation and cryoablation of lung tumors. J Thorac Imaging. 2011; 26(2):162-74. DOI: 10.1097/RTI.0b013e3182171b75. View

Qu H, Li R, Liu Z, Zhang J, Luo R . Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2013; 6(11):2644-50. PMC: 3816842. View

Majeti R, Chao M, Alizadeh A, Pang W, Jaiswal S, Gibbs Jr K . CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138(2):286-99. PMC: 2726837. DOI: 10.1016/j.cell.2009.05.045. View

Shi S, Tang X, Tian J, Chang C, Li P, Qi J . Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother. 2014; 37(4):250-5. DOI: 10.1097/CJI.0000000000000015. View

Grilli R, Oxman A, Julian J . Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol. 1993; 11(10):1866-72. DOI: 10.1200/JCO.1993.11.10.1866. View

Goldberg S, Grassi C, Cardella J, Charboneau J, Dodd 3rd G, Dupuy D . Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005; 16(6):765-78. DOI: 10.1097/01.RVI.0000170858.46668.65. View

Wright S . Immunotherapy of breast cancer. Expert Opin Biol Ther. 2012; 12(4):479-90. DOI: 10.1517/14712598.2012.665445. View

10.

Plate J . Clinical trials of vaccines for immunotherapy in pancreatic cancer. Expert Rev Vaccines. 2011; 10(6):825-36. DOI: 10.1586/erv.11.77. View

11.

Dick J . Stem cell concepts renew cancer research. Blood. 2008; 112(13):4793-807. DOI: 10.1182/blood-2008-08-077941. View

12.

Visvader J . Cells of origin in cancer. Nature. 2011; 469(7330):314-22. DOI: 10.1038/nature09781. View

13.

Yuanying Y, Lizhi N, Feng M, Xiaohua W, Jianying Z, Fei Y . Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology. 2013; 67(2):235-40. DOI: 10.1016/j.cryobiol.2013.08.001. View

14.

Maiwand M, Evans J, Beeson J . The application of cryosurgery in the treatment of lung cancer. Cryobiology. 2004; 48(1):55-61. DOI: 10.1016/j.cryobiol.2003.12.003. View

15.

Jin L, Lee E, Ramshaw H, Busfield S, Peoppl A, Wilkinson L . Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5(1):31-42. DOI: 10.1016/j.stem.2009.04.018. View

16.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

17.

Zhao M, Li H, Li L, Zhang Y . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 2014; 7(5):1403-1407. PMC: 3991503. DOI: 10.3892/etm.2014.1574. View

18.

Lundin A, Driscoll B . Lung cancer stem cells: progress and prospects. Cancer Lett. 2012; 338(1):89-93. PMC: 3686996. DOI: 10.1016/j.canlet.2012.08.014. View

19.

Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K . Molecular pathological approaches to human tumor immunology. Pathol Int. 2009; 59(4):205-17. DOI: 10.1111/j.1440-1827.2009.02353.x. View

20.

Chen Y, Zhong H . [The utilization and limitation of CD133 epitopes in lung cancer stem cells research]. Zhongguo Fei Ai Za Zhi. 2011; 14(10):825-9. PMC: 5999939. DOI: 10.3779/j.issn.1009-3419.2011.10.10. View